GlaxoSmithKline PLC (GSK)

SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Andrew Witty , Divisional President/Director/CEO
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Andrew Witty, Divisional President/Director/CEO

980 Great West Road

Brentford, Middlesex, TW8 9GS

EN Map it

Phone: 4402080475000

Fax: 4402080477807

www.gsk.com

Latest news from Portfolio


Overview

The Company and its subsidiary is engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.

Portfolio Articles
  • Just What the Doctor Ordered
    GlaxoSmithKline and Eli Lilly break with the rest of the drug industry on pricing and on disclosing studies and doctors' perks.
    May 21 2008
  • The Ultimare Cure
    The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed.
    May 12 2008
  • Fountain of Money
    Sirtris Pharmaceuticals and its novel drugs to combat age-related diseases and to increase life span are snatched up by GlaxoSmithKline for $720 million.
    Apr 23 2008
  • Dollar Daze
    Weakling currency is pummeling European companies in the U.S. 
    Oct 17 2007
  • Passing the Glaxo Drug Test
    Pharmaceutical giant picks its next C.E.O.
    Oct 08 2007

See more news on this company

Portfolio Blogs
News From Around the Web
powered by  inform

Employees

Number of Employees: 103,000
Revenue per Employee: $455,514

Top Executives

Marc Dunoyer, Divisional President
Eddie Gray, President, Divisional
Dr. Russell Greig, Divisional President

Julian Heslop, CFO/Director
John Clarke, Divisional President
Dan Phelan, Divisional Senior VP

Bill Louv, Chief Information Officer
Duncan Learmouth, Senior VP, Divisional
Christopher Viehbacher, Divisional President/Director

Dr. David Pulman, Divisional President

Board of Directors

Simon Bicknell, Secretary
Sir Crispin Davis, Director
Sir Ian Prosser, Director

Sir Christopher Gent, Chairman of the Board/Director
Dr. Moncef Slaoui, Ph.D., Chairman of the Board, Divisional/Director

Julian Heslop, CFO/Director
Tom de Swaan, Director
Lawrence Culp, Director

Sir Deryck Maughan, Director
Christopher Viehbacher, Divisional President/Director

Financials

Quarterly
Annual

Income Statement 04/2008 02/2008 10/2007 07/2007
Sales 1.96 Bil. 2.49 Bil. 1.69 Bil. 1.92 Bil.
Gross Operating Profit 9.32 Bil. 9.37 Bil. 9.51 Bil. 9.47 Bil.
Operating Income before D & A (EBITDA) 4.36 Bil. 3.68 Bil. 4.63 Bil. 4.19 Bil.
Total Income Before Interest Expenses (EBIT) 4.09 Bil. 3.28 Bil. 4.09 Bil. 4.05 Bil.
Total Net Income 2.59 Bil. 2.1 Bil. 2.68 Bil. 2.68 Bil.
Basic EPS, Total 0.97 0.78 0.97 0.96
Diluted EPS, Total 0.97 0.78 0.97 0.95

BALANCE STATEMENT 04/2008 02/2008 10/2007 07/2007
Cash and Equivalents 4.26 Bil. 6.71 Bil. 4.19 Bil. 3.8 Bil.
Total Assets 24.86 Bil. 27.05 Bil. 23.28 Bil. 22.03 Bil.
Total Liabilities 18.4 Bil. 20.54 Bil. 18.47 Bil. 14.47 Bil.
Total Capitalization 33.78 Bil. 33.09 Bil. 30.2 Bil. 31.76 Bil.

Cash Flow 04/2008 02/2008 10/2007 07/2007
Net Cash From Continuing Operations 3.57 Bil. 12.23 Bil. 9.77 Bil. 5.89 Bil.
Net Cash From Investing Activities -468 Mil. -5.97 Bil. -3.34 Bil. -2.57 Bil.
Net Cash From Financing Activities -5.6 Bil. -3.46 Bil. -6.61 Bil. -3.66 Bil.
Net Change in Cash & Cash Equivalents -2.51 Bil. 2.8 Bil. -172 Mil. -371 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 7.91 Bil. 7.94 Bil. 6.64 Bil. 6.55 Bil.
Gross Operating Profit 37.18 Bil. 37.55 Bil. 30.62 Bil. 32.48 Bil.
Operating Income before D & A (EBITDA) 16.78 Bil. 16.57 Bil. 12.75 Bil. 13.5 Bil.
Total Income Before Interest Expenses (EBIT) 15.69 Bil. 15.89 Bil. 12.36 Bil. 12.32 Bil.
Total Net Income 10.35 Bil. 10.56 Bil. 8.07 Bil. 8.25 Bil.
Basic EPS, Total 3.75 3.74 3 2.88
Diluted EPS, Total 3.75 3.7 3 2.87

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 6.71 Bil. 3.93 Bil. 7.24 Bil. 2.23 Bil.
Total Assets 27.05 Bil. 21.53 Bil. 22.67 Bil. 26.14 Bil.
Total Liabilities 20.54 Bil. 14.23 Bil. 16.36 Bil. 16.72 Bil.
Total Capitalization 33.09 Bil. 27.54 Bil. 21.64 Bil. 19.76 Bil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations 12.23 Bil. 8.53 Bil. 10.25 Bil. 9.02 Bil.
Net Cash From Investing Activities -5.97 Bil. -2.98 Bil. -2.86 Bil. -2.12 Bil.
Net Cash From Financing Activities -3.46 Bil. -9.39 Bil. -5.01 Bil. -7.54 Bil.
Net Change in Cash & Cash Equivalents 2.8 Bil. -4.33 Bil. 2.78 Bil. -644 Mil.

powered by Interactive Data







News Volume

31 days volume

100%
80%
60%
40%
20%
0
September
October

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented